Xenon Pharmaceuticals Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Xenon Pharmaceuticals Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $16.0K | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $264.0K | Mar 7, 2018 |
| FY2017 | Jun 30, 2017 | $15.0K | Mar 7, 2018 |
| FY2017 | Mar 31, 2017 | $16.0K | Mar 7, 2018 |
| FY2017 | Dec 31, 2016 | $376.0K | Mar 7, 2018 |
| FY2017 | Sep 30, 2016 | $413.0K | Mar 7, 2018 |
| FY2017 | Jun 30, 2016 | $413.0K | Mar 7, 2018 |
| FY2017 | Mar 31, 2016 | $601.0K | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $3.23M | Mar 8, 2017 |
| FY2016 | Sep 30, 2015 | $4.29M | Mar 8, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2017 | $311.0K | Mar 6, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($345.91M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($234.33M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($182.39M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($125.37M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($78.88M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($28.84M) | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | ($41.60M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($34.50M) | Mar 9, 2020 |
| FY2017 | Dec 31, 2017 | ($8.07M) | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | ($7.74M) | Mar 7, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($373.07M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($279.30M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($214.05M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($129.14M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($78.99M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($31.30M) | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | ($42.82M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($38.04M) | Mar 9, 2020 |
| FY2017 | Dec 31, 2017 | ($8.05M) | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | ($8.64M) | Mar 7, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.94M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $210.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $167.51M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $105.77M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $75.46M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $50.52M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $38.85M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $23.63M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $25.57M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $19.83M | Mar 7, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($279.12M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($181.39M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($151.11M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($101.03M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($69.50M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($48.12M) | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | ($4.71M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($34.72M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($28.73M) | Mar 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $799.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $5.62M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.89M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.05M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.64M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $1.24M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $507.0K | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $315.0K | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $279.0K | Mar 7, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $633.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $798.14M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $964.80M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $754.15M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $572.01M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $189.19M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $147.70M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $122.43M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $46.12M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $67.49M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $43.24M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $36.88M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $32.65M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $21.97M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $17.83M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $55.72M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $19.13M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $10.19M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $3.59M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $581.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $754.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $927.92M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $721.50M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $550.03M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $171.36M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $91.98M | Mar 1, 2023 |
| FY2020 | Dec 31, 2018 | $103.30M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $35.93M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $63.90M | Mar 6, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.25B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($899.47M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($665.14M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($482.75M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($357.37M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($278.49M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($249.66M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($207.89M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($173.39M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($142.68M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $142.71M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $148.64M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $57.24M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $175.69M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $45.01M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $24.76M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $67.75M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $20.49M | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $17.10M | Mar 6, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2018 | Dec 31, 2018 | (1) | Mar 6, 2019 |
| FY2017 | Dec 31, 2017 | 0 | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 7, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Mar 7, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2018 | Dec 31, 2018 | (1) | Mar 6, 2019 |
| FY2017 | Dec 31, 2017 | 0 | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 7, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Mar 7, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 80.01M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 76.42M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 75.37M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 62.59M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 51.63M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 35.01M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 28.14M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 25.75M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 18.00M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 17.93M | Mar 7, 2018 |